Leuven (BELGIUM), Madrid (SPAIN) - March 12, 2013 - TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect® will obtain national reimbursement in Spain.
"We are delighted with the decision of the Spanish health authorities to reimburse ChondroCelect, and look forward to working with Spanish orthopedic centers of excellence to routinely make this breakthrough therapy available to the right patients in Spain," said Eduardo Bravo, CEO of TiGenix. "After obtaining national reimbursement in the Netherlands last year, this constitutes another major step in improving patient access to this innovative therapy. We keep working to obtain national reimbursement in other European countries later this year."
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com
Hans Herklots
hans.herklots@tigenix.com
+32 16 39 79 73
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.
ChondroCelect is the first and currently only cell therapy that has been granted market authorisation by the European Union in accordance with the Advanced Therapy Medicinal Product regulation EC1394/2007. For more information, including the European Public Assessment Report (EPAR), prescribing information, and the Summary of Product Characteristics (SPC) please visit the European Medicines Agency (EMA) website at www.ema.europa.eu.